UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions

HELLERUP, Denmark, SAN FRANCISCO and SUZHOU, China: HELLERUP, Denmark, SAN FRANCISCO and SUZHOU, China, Sept. 28, 2021 /PRNewswire/ -- UNION therapeutics A/S ('UNION'), a privately-held, multi-asset, clinical stage, pharmaceutical company focused on immunology and infectious diseases, and Innovent Biologics (HK) Limited, a subsidiary of Innovent Biologics, Inc. (HKEX: 01801, 'Innovent'),...

Click to view original post